[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO6670519A2 - Métodos para tratar infecciones bacterianas recurrentes - Google Patents

Métodos para tratar infecciones bacterianas recurrentes

Info

Publication number
CO6670519A2
CO6670519A2 CO12208172A CO12208172A CO6670519A2 CO 6670519 A2 CO6670519 A2 CO 6670519A2 CO 12208172 A CO12208172 A CO 12208172A CO 12208172 A CO12208172 A CO 12208172A CO 6670519 A2 CO6670519 A2 CO 6670519A2
Authority
CO
Colombia
Prior art keywords
methods
bacterial infections
recurrent bacterial
treat recurrent
treat
Prior art date
Application number
CO12208172A
Other languages
English (en)
Inventor
Youe Kong Shue
Scherwood Gorbach
Pamela Sears
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6670519(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of CO6670519A2 publication Critical patent/CO6670519A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Métodos para tratar infecciones gastrointestinales (GI) recurrentes de Clostridium difficile en un sujeto, que comprenden administrarle al sujeto una cantidad eficaz de un compuesto de la presente invención.
CO12208172A 2010-05-18 2012-11-16 Métodos para tratar infecciones bacterianas recurrentes CO6670519A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34592310P 2010-05-18 2010-05-18

Publications (1)

Publication Number Publication Date
CO6670519A2 true CO6670519A2 (es) 2013-05-15

Family

ID=44992320

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12208172A CO6670519A2 (es) 2010-05-18 2012-11-16 Métodos para tratar infecciones bacterianas recurrentes

Country Status (9)

Country Link
US (1) US20140315838A1 (es)
AU (1) AU2011255633B2 (es)
BR (1) BR112012029262A8 (es)
CA (1) CA2799531A1 (es)
CL (1) CL2012003202A1 (es)
CO (1) CO6670519A2 (es)
MX (1) MX2012013372A (es)
PE (1) PE20130308A1 (es)
WO (1) WO2011146624A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9579354B2 (en) * 2012-01-23 2017-02-28 Santalis Pharmaceuticals, Inc. Sandalwood oil and its uses related to clostridium infections
WO2013138748A1 (en) * 2012-03-16 2013-09-19 Optimer Pharmaceuticals, Inc. Prevention of clostridium difficile infection in high risk patients
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins

Also Published As

Publication number Publication date
BR112012029262A2 (pt) 2017-07-11
BR112012029262A8 (pt) 2018-06-12
CA2799531A1 (en) 2011-11-24
WO2011146624A9 (en) 2012-05-10
AU2011255633B2 (en) 2014-09-11
US20140315838A1 (en) 2014-10-23
PE20130308A1 (es) 2013-04-06
CL2012003202A1 (es) 2013-07-12
MX2012013372A (es) 2013-05-01
AU2011255633A1 (en) 2013-01-10
WO2011146624A2 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
CY1122278T1 (el) Αντι il-36r αντισωματα
WO2012106735A3 (en) Plasma-assisted skin treatment
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
EA201390274A1 (ru) Борсодержащие малые молекулы
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
BR112012026112A2 (pt) método de tratar obesidade usando moduladores de inflamação antioxidantes
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201690582A1 (ru) Модуляторы фактора в комплемента
EA201490559A1 (ru) Композиция для лечения свища
WO2012116010A3 (en) Antibiotic tolerance inhibitors
MX354988B (es) Formulaciones de anticuerpo y metodos.
CR20130539A (es) Triazolopiridinas
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
BR112013006567A2 (pt) métodos e composições para tratamento de câncer de pulmão
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
IN2015DN03113A (es)
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
GB201316955D0 (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
CO6670519A2 (es) Métodos para tratar infecciones bacterianas recurrentes
CO7121334A2 (es) Formulaciones vesiculares